CSPCY (CSPC Pharmaceutical Group) Scaled Net Operating Assets: N/A (As of Dec. 2025)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
79 GF Score
Price $3.58
GF Value $3.37
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CSPC Pharmaceutical Group's operating assets for the quarter that ended in Dec. 2025 was $5,371 Mil. CSPC Pharmaceutical Group's operating liabilities for the quarter that ended in Dec. 2025 was $1,634 Mil. CSPC Pharmaceutical Group's Total Assets for the quarter that ended in Sep. 2025 was $0 Mil. Therefore, CSPC Pharmaceutical Group's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was N/A.

CSPC Pharmaceutical Group Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Scaled Net Operating Assets Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.48 0.53 0.55 0.61

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CSPCY vs LLY, JNJ, ABBV: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Scaled Net Operating Assets falls into.


CSPCY
79GF Score
CSPC Pharmaceutical Group Ltd CSPCY
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CSPC Pharmaceutical Group's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(5371.484-1633.73)/6096.803
=0.61

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6630.213 - 1258.729
=5371.484

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1724.755 - 25.655 - 65.37
=1633.73

CSPC Pharmaceutical Group's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(5371.484-1633.73)/0
=N/A

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6630.213 - 1258.729
=5371.484

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1724.755 - 25.655 - 65.37
=1633.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $3.58 is trading 6.4% above its estimated GF Value™ of $3.37. GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.

Key valuation signals for CSPCY:

  • Scaled Net Operating Assets: N/A
  • GF Value™: $3.37 vs. price of $3.58 (6.4% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
79GF Score

Get the complete analysis for CSPCY

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.58
Price
$3.37
GF Value